# Episode 502: AUA 2026 and FDA bladder cancer meeting

Page: https://stenobird.com/podcast/the-uromigos-1214845/episode-502-aua-2026-and-fda-bladder-cancer-meeting
Text version: https://stenobird.com/podcast/the-uromigos-1214845/episode-502-aua-2026-and-fda-bladder-cancer-meeting.md
Podcast: [The Uromigos](https://stenobird.com/podcast/the-uromigos-1214845)
Published: 2026-05-20T15:22:24+00:00
Episode link: https://podcasters.spotify.com/pod/show/the-uromigos/episodes/Episode-502-AUA-2026-and-FDA-bladder-cancer-meeting-e3jlaf2
Audio file: https://anchor.fm/s/13347ea8/podcast/play/120285090/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-20%2F424548128-44100-2-4ce93ed7c5d5a.m4a
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-uromigos-1214845/episodes/episode-502-aua-2026-and-fda-bladder-cancer-meeting
Duration seconds: 2116

## Resource

In this episode, Brian and Tom engage with Ashish Kamat to discuss the recent FDA meeting focused on bladder cancer treatments, particularly the nuances between CIS and papillary disease. They explore the challenges of drug approvals, the importance of randomized trials, and the emerging data on Deltalimagene, a non-viral gene therapy. The conversation highlights the complexities of treatment options, the need for robust clinical trials, and the future landscape of bladder cancer therapies

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-uromigos-1214845/episodes/episode-502-aua-2026-and-fda-bladder-cancer-meeting/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-uromigos-1214845/episode-502-aua-2026-and-fda-bladder-cancer-meeting.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.